Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$65.42 USD
+0.15 (0.23%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $65.42 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GILD 65.42 +0.15(0.23%)
Will GILD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GILD
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Other News for GILD
Amgen’s Blincyto data send Cullinan higher
Analysts Are Neutral on These Healthcare Stocks: Edwards Lifesciences (EW), Gilead Sciences (GILD)
June 7th Options Now Available For Gilead Sciences (GILD)
3 Dividend Stocks to Buy at a 52-Week Low in April
Gilead Sciences declares $0.77 dividend